We expect that additional studies on the Ca2+ signaling mechanisms and CaM-regulated systems, affecting the functions of oncogenic non-receptor tyrosine kinases belonging to the Src family, may identify new therapeutic targets that can block the hyperactivity and/or overexpression of these kinases in tumor cells with specificity, in order to treat patients with SFK-driven cancers. This evidence concerns the gene SRC and neoplasm.